Anbio BiotechnologyNNNN +2.88%24 PB Ratio is 18.14 as of Jul. 04, 2026, which is 54% below its 10-year median of 39.67. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Anbio Biotechnology ranks worse than 96.44% on this metric.
Anbio Biotechnology stock PB Ratio (=18.14) is close to 1-year low of 18.14.
The historical rank and industry rank for Anbio Biotechnology's PB Ratio or its related term are showing as below:
NNNN'
s PB Ratio Range Over the Past 10 Years
Min: 14.72 Med: 39.67 Max: 130.26
Current: 18.14
During the past 5 years, Anbio Biotechnology's highest PB Ratio was 130.26. The lowest was 14.72. And the median was 39.67.
NNNN's PB Ratio is ranked worse than 96.44% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs NNNN: 18.14
During the past 12 months, Anbio Biotechnology's average Book Value Per Share Growth Rate was 75.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 33.90% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Anbio Biotechnology was 89.10% per year. The lowest was 33.90% per year. And the median was 61.50% per year.
Back to Basics: PB Ratio
Anbio Biotechnology (NAS:NNNN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Anbio Biotechnology PB Ratio Related Terms
Anbio Biotechnology PB Ratio Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Anbio Biotechnology (NNNN) has a PB Ratio of 18.14 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anbio Biotechnology and its competitors. This is 54% below median its historical median of 39.67. Over the past decade, Anbio Biotechnology's PB Ratio has ranged from 14.72 to 130.26. According to the industry distribution chart, Anbio Biotechnology ranks #759 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 96.4%.
Is Anbio Biotechnology's PB Ratio too high?
Anbio Biotechnology's current PB Ratio of 18.14 is 54% below median its 10-year median of 39.67. Over the past 10 years, this metric has ranged from a low of 14.72 to a high of 130.26. The Medical Devices & Instruments industry median PB Ratio is 2.09. Anbio Biotechnology's value of 18.14 is 767.9% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #759 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's PB Ratio compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #759 out of 787 companies for PB Ratio. This places Anbio Biotechnology in the lower half of its industry. The industry median PB Ratio is 2.09. Anbio Biotechnology's value of 18.14 is 767.9% above this benchmark. Historically, Anbio Biotechnology's own PB Ratio has ranged from 14.72 to 130.26 over the past decade. While the company's 10-year median is 39.67 vs. the industry median of 2.09, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.09, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current PB Ratio of 18.14 is 767.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current PB Ratio is 18.14, which is 54% below median its own 10-year median of 39.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current PB Ratio of 18.14. The current PB Ratio is 18.14, which is 54% below median its 10-year median of 39.67 and 767.9% above the Medical Devices & Instruments industry median of 2.09. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current PB Ratio is 18.14 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
